ATE243760T1 - Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen - Google Patents

Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen

Info

Publication number
ATE243760T1
ATE243760T1 AT95916864T AT95916864T ATE243760T1 AT E243760 T1 ATE243760 T1 AT E243760T1 AT 95916864 T AT95916864 T AT 95916864T AT 95916864 T AT95916864 T AT 95916864T AT E243760 T1 ATE243760 T1 AT E243760T1
Authority
AT
Austria
Prior art keywords
carcinomas
treatment
types
minimal residual
micrometastasization
Prior art date
Application number
AT95916864T
Other languages
English (en)
Inventor
Rudolf Henrikus Brakenhoff
Dongen Augustina Antonius Van
Original Assignee
Stichting Keel Neus En Oorheel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Keel Neus En Oorheel filed Critical Stichting Keel Neus En Oorheel
Application granted granted Critical
Publication of ATE243760T1 publication Critical patent/ATE243760T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT95916864T 1995-05-10 1995-05-10 Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen ATE243760T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL1995/000168 WO1996035808A1 (en) 1995-05-10 1995-05-10 Methods for detection and therapy of squamous cell carcinoma and bladder carcinoma, in particular for determining the presence and treatment of minimal residual disease, micrometastases or dissemination of such carcinoma types

Publications (1)

Publication Number Publication Date
ATE243760T1 true ATE243760T1 (de) 2003-07-15

Family

ID=19865519

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916864T ATE243760T1 (de) 1995-05-10 1995-05-10 Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen

Country Status (5)

Country Link
EP (1) EP0828852B1 (de)
AT (1) ATE243760T1 (de)
AU (1) AU2375895A (de)
DE (1) DE69531167D1 (de)
WO (1) WO1996035808A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
CA2343320A1 (en) * 1998-09-18 2000-03-30 The Rockefeller University Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
GB201213652D0 (en) * 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target

Also Published As

Publication number Publication date
WO1996035808A1 (en) 1996-11-14
EP0828852A1 (de) 1998-03-18
EP0828852B1 (de) 2003-06-25
DE69531167D1 (de) 2003-07-31
AU2375895A (en) 1996-11-29

Similar Documents

Publication Publication Date Title
Stanley et al. Identification and partial characterization of pemphigoid antigen extracted from normal human skin
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE299180T1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
ATE165980T1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
ATE386117T1 (de) Prostattumor polynukleotid- und antigenzusammensetzungen
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
KR960703014A (ko) Mhc 분자 hla-c-클론 10과 복합체를 형성하는 분리된 펩티드 및 그것의 사용(isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof)
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
DE69637148D1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000001813A3 (en) Peptide inhibitors of androgen-independent activation of androgen receptor
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
ATE215830T1 (de) Verfahren zur detektion und behandlung von individuen mit abnormal hla-a2/tyrosinase- peptidantigenen exprimierenden zellen
ATE243760T1 (de) Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
DE69739653D1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
ATE203768T1 (de) Diagnose und behandlung von streptococus oder enterococus infektionen
NO962596L (no) Nytt tumorsupressorgen
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties